On May 13, 2020, BioMed X, an independent Heidelberg-based research institute, announced the launch of its new Rapid Antiviral Response Platform (RAR). BioMed X will develop an arsenal of ultrafast new antiviral drug discovery, development and mass-manufacturing tools that will allow the identification of a new viral pathogen to 10,000 doses of a safe and potent new medication in less than 6 months.